Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice

Journal of Veterinary Science

Volumn 8, Issue 4, 2007, Pages 383-392

  Sung, Jae Shin ^a,c   Seung, Won Shin ^a   Mi, Lan Kang ^a   Deog, Yong Lee ^a   Yang, Moon Sik ^b   Jang, Yong Suk ^b   Han, Sang Yoo ^a  

^a Seoul National University   (South Korea)

^b Chonbuk National University   (South Korea)

^c Chungnam National University   (South Korea)

Author keywords

Actinobacillus pleuropneumoniae; Apx toxins; Oral immunization; Protective immunity

Indexed keywords

ACTINOBACILLUS PLEUROPNEUMONIAE; ACTINOBACILLUS PLEUROPNEUMONIAE SEROVAR 5; MUS; SACCHAROMYCES CEREVISIAE;

EID: 37349038473     PISSN: 1229845X     EISSN: None     Source Type: Journal    
DOI: 10.4142/jvs.2007.8.4.383     Document Type: Article

References (40)

1. Bathurst IC. Protein expression in yeast as an approach to production of recombinant malaria antigens. Am J Trop Med Hyg 1994, 50, 20-26.
2. Beier R, Gebert A. Kinetics of particle uptake in the domes of Peyer's patches. Am J Physiol 1998, 275, G130-137.
3. Blanquet S, Antonelli R, Laforet L, Denis S, Marol-Bonnin S, Alric M. Living recombinant Saccharomyces cerevisiae secreting proteins or peptides as a new drug delivery system in the gut. J Biotechnol 2004, 110, 37-49.
4. Blanquet S, Meunier JP, Minekus M, Marol-Bonnin S, Alric M. Recombinant Saccharomyces cerevisiae expressing P450 in artificial digestive systems: a model for biodetoxication in the human digestive environment. Appl Environ Microbiol 2003, 69, 2884-2892.
5. Boekema BK, Kamp EM, Smits MA, Smith HE, Stockhofe-Zurwieden N. Both ApxI and ApxII of Actinobacillus pleuropneumoniae serotype 1 are necessary for full virulence. Vet Microbiol 2004, 100, 17-23.
6. Bosse JT, Janson H, Sheehan BJ, Beddek AJ, Rycroft AN, Kroll JS, Langford PR. Actinobacillus pleuropneumoniae: pathobiology and pathogenesis of infection. Microbes Infect 2002, 4, 225-235.
7. Bouvet JP, Decroix N, Pamonsinlapatham P. Stimulation of local antibody production: parenteral or mucosal vaccination? Trends Immunol 2002, 23, 209-213.
8. Bowersock TL, Shalaby WS, Levy M, Samuels ML, Lallone R, White MR, Borie DL, Lehmeyer J, Park K. Evaluation of an orally administered vaccine, using hydrogels containing bacterial exotoxins of Pasteurella haemolytica, in cattle. Am J Vet Res 1994, 55, 502-509.
9. Broug-Holub E, Toews GB, van Iwaarden JF, Strieter RM, Kunkel SL, Paine R, Standiford TJ. Alveolar macrophages are required for protective pulmonary defenses in murine Klebsiella pneumonia: elimination of alveolar macrophages increases neutrophil recruitment but decreases bacterial clearance and survival. Infect Immun 1997, 65, 1139-1146.
10. Choi C, Kwon D, Min K, Chae C. In-situ hybridization for the detection of inflammatory cytokines (IL-1, TNF-alpha and IL-6) in pigs naturally infected with Actinobacillus pleuropneumoniae. J Comp Pathol 1999, 121, 349-356.
11. Cox E, Van der Stedea Y, Verdonck F, Snoeck V, Van den Broeck W, Goddeeris B. Oral immunisation of pigs with fimbrial antigens of enterotoxigenic E. coli: an interesting model to study mucosal immune mechanisms. Vet Immunol Immunopathol 2002, 87, 287-290.
12. Dietrich G, Griot-Wenk M, Metcalfe IC, Lang AB, Viret JF. Experience with registered mucosal vaccines. Vaccine 2003, 21, 678-683.
13. Externest D, Meckelein B, Schmidt MA, Frey A. Correlations between antibody immune responses at different mucosal effector sites are controlled by antigen type and dosage. Infect Immun 2000, 68, 3830-3839.
14. Fernandez MI, Pedron T, Tournebize R, Olivo-Marin JC, Sansonetti PJ, Phalipon A. Anti-inflammatory role for intracellular dimeric immunoglobulin a by neutralization of lipopolysaccharide in epithelial cells. Immunity 2003, 18, 739-749.
15. Frey J. Virulence in Actinobacillus pleuropneumoniae and RTX toxins. Trends Microbiol 1995, 3, 257-261.
16. Fuller TE, Martin S, Teel JF, Alaniz GR, Kennedy MJ, Lowery DE. Identification of Actinobacillus pleuropneumoniae virulence genes using signature-tagged mutagenesis in a swine infection model. Microb Pathog 2000, 29, 39-51.
17. Haga Y, Ogino S, Ohashi S, Ajito T, Hashimoto K, Sawada T. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia. J Vet Med Sci 1997, 59, 115-120.
18. Hensel A, van Leengoed LA, Szostak M, Windt H, Weissenbock H, Stockhofe-Zurwieden N, Katinger A, Stadler M, Ganter M, Bunka S, Pabst R, Lubitz W. Induction of protective immunity by aerosol or oral application of candidate vaccines in a dose-controlled pig aerosol in fection model. J Biotechnol 1996, 44, 171-181.
19. Lauterslager TG, Hilgers LA. Efficacy of oral administration and oral intake of edible vaccines. Immunol Lett 2002, 84, 185-190.
20. Lauterslager TG, Stok W, Hilgers LA. Improvement of the systemic prime/oral boost strategy for systemic and local responses. Vaccine 2003, 21, 1391-1399.
21. Losinger WC. Economic impacts of reduced pork production associated with the diagnosis of Actinobacillus pleuropneumoniae on grower/finisher swine operations in the United States. Prev Vet Med 2005, 68, 181-193.
22. Ogra PL, Faden H, Welliver RC. Vaccination strategies for mucosal immune responses. Clin Microbiol Rev 2001, 14, 430-445.
23. Olas K, Butterweck H, Teschner W, Schwarz HP, Reipert B. Immunomodulatory properties of human serum immunoglobulin A: anti-inflammatory and pro-inflammatory activities in human monocytes and peripheral blood mononuclear cells. Clin Exp Immunol 2005, 140, 478-490.
24. Pabst R, Binns RM. The immune system of the respiratory tract in pigs. Vet Immunol Immunopathol 1994, 43, 151-156.
25. Pascual DW, Trunkle T, Sura J. Fimbriated Salmonella enterica serovar typhimurium abates initial inflammatory responses by macrophages. Infect Immun 2002, 70, 4273-4281.
26. Prideaux CT, Lenghaus C, Krywult J, Hodgson AL. Vaccination and protection of pigs against pleuropneumonia with a vaccine strain of Actinobacillus pleuropneumoniae produced by site-specific mutagenesis of the ApxII operon. Infect Immun 1999, 67, 1962-1966.
27. Rappuoli R, Pizza M, Douce G, Dougan G. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999, 20, 493-500.
28. Reimer D, Frey J, Jansen R, Veit HP, Inzana TJ. Molecular investigation of the role of ApxI and ApxII in the virulence of Actinobacillus pleuropneumoniae serotype 5. Microb Pathog 1995, 18, 197-209.
29. Saegusa S, Totsuka M, Kaminogawa S, Hosoi T. Candida albicans and Saccharomyces cerevisiae induce interleukin-8 production from intestinal epithelial-like Caco-2 cells in the presence of butyric acid. FEMS Immunol Med Microbiol 2004, 41, 227-235.
30. Schreuder MP, Deen C, Boersma WJ, Pouwels PH, Klis FM. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 1996, 14, 383-388.
31. Schreuder MP, Mooren AT, Toschka HY, Verrips CT, Klis FM. Immobilizing proteins on the surface of yeast cells. Trends Biotechnol 1996, 14, 115-120.
32. Seah JN, Frey J, Kwang J. The N-terminal domain of RTX toxin ApxI of Actinobacillus pleuropneumoniae elicits protective immunity in mice. Infect Immun 2002, 70, 6464-6467.
33. Shin SJ, Cho YW, Yoo HS. Cloning, sequencing and expression of apxIA, IIA, IIIA of Actinobacillus pleuropneumoniae isolated in Korea. Korean J Vet Res 2003, 43, 247-253.
34. Shin SJ, Bae JL, Cho YW, Lee DY, Kim DH, Yang MS, Jang YS, Yoo HS. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunol Med Microbiol 2005, 43, 155-164.
35. Shin SJ, Bae JL, Cho YW, Yang MS, Kim DH, Jang YS, Yoo HS. Expression of apxIA of Actinobacillus pleuropneumoniae in Saccharomyces cerevisiae. J Vet Sci 2003, 4, 225-228.
36. Shin SJ, Wu CW, Steinberg H, Talaat AM. Identification of novel virulence determinants in Mycobacterium paratuberculosis by screening a library of insertional mutants. Infect Immun 2006, 74, 3825-3833.
37. Silin DS, Lyubomska V. Overcoming immune tolerance during oral vaccination against Actinobacillus pleuropneumoniae. J Vet Med B Infect Dis Vet Public Health 2002, 49, 169-175.
38. Stubbs AC, Martin KS, Coeshott C, Skaates SV, Kuritzkes DR, Bellgrau D, Franzusoff A, Duke RC, Wilson CC. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nat Med 2001, 7, 625-629.
39. Tonpitak W, Baltes N, Hennig-Pauka I, Gerlach GF. Construction of an Actinobacillus pleuropneumoniae serotype 2 prototype live negative-marker vaccine. Infect Immun 2002, 70, 7120-7125.
40. Williams AE, Edwards L, Humphreys IR, Snelgrove R, Rae A, Rappuoli R, Hussell T. Innate imprinting by the modified heat-labile toxin of Escherichia coli (LTK63) provides generic protection against lung infectious disease. J Immunol 2004, 173, 7435-7443.